An interventional study of Vielight Neuro Rx Gamma and Sham Device in Bipolar, Bipolar Disorder (BD) and Bipolar Disorder Depression, sponsored by Vielight Inc.. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Vielight Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Bipolar Disorder with a site in Canada — 24 open to participants now, 28 under way, 4 of them phase 3. Bipolar Disorder · Canada.
Among the 134 studies in Bipolar Disorder with a site in Canada, this one is the 61st largest by planned enrollment of the 118 interventional ones that give a count, is one of 6 that started in 2026, is one of 57 with no phase, reaches primary completion later than 12 of the 27 other live ones, and was the 125th registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →24 of the 134 studies in Bipolar Disorder with a site in Canada are open now. Recruiting first, the newest first:
Joshua Rosenblat · Sites in Canada
Ages 18–70
Lakshmi N Yatham · Sites in Canada
Ages 19–65
McMaster University · Sites in Canada
Ages 18–35
University of Ottawa · Sites in Canada
Ages 18–55
University of Manitoba · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 21 · Phase 3 27 · Phase 4 10
First in 1999; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 42 across the 118 interventional studies, 175 across the 16 observational. Of the 88 that completed or were terminated, 14 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 134 have an industry lead sponsor. The 10 most frequent:
Vielight Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Vielight Inc. has 1 study filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
5 of the studies in Bipolar Disorder with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06560957University of OttawaSYNCED - SYNChronized Eating in Bipolar Depression Study | 2026-12-26 |
| NCT07213492McMaster UniversityMultimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder | 2027-05-01 |
| NCT01980147Nova Scotia Health AuthoritySkills for Wellness | 2027-06-30 |
| NCT07510646Vielight Inc.Transcranial Photobiomodulation for Bipolar Depression | 2027-07-01 |
| NCT07108257Sunnybrook Health Sciences CentreMagnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression | 2027-09-16 |
Add all 5 to your calendar (.ics) → With an account.
Among the 134 studies in Bipolar Disorder with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study the effectiveness and safety of light therapy device targeted at the brain using a wearable device, the Vielight RX Gamma as a treatment for bipolar depression. Up to forty patients with bipolar disorder will be enrolled into the study and will either receive active treatment with the Vielight RX Gamma or sham (inactive device). They will be administered the devices in clinic 5days/week for 6 weeks. Changes in disease symptoms, cognitive function, pain, quality of life and rest EEG changes will be assessed.
Photobiomodulation (PBM) refers to the application of low levels of red or near-infrared (NIR) light to either stimulate or inhibit biological cells and tissues involving photochemical mechanisms. Transcranial PBM (tPBM), targeting delivery of light energy to the brain, is associated with increased cerebral blood flow, oxygen availability and consumption, adenoside triphophosphate (ATP) production, and improved mitochondrial activity. More recently, tPBM has demonstrated its value as a treatment for neurological and neurodegenerative conditions. Evidence of mitochondrial dysfunction in patients with BD suggests that PBM may have therapeutic benefits for patients with BD. The primary objective of this study is to confirm the safety and efficacy of using tPBM at 40Hz stimulation in improving symptoms of depression in patients diagnosed with bipolar depression.The study will be a single-blind randomized sham-controlled pilot trial with subjects receiving treatment 5 days/week for 6 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of bipolar depression
Exclusion Criteria:
Currently in manic or mixed episode, as measured by Young Mania Rating Scale (YMRS) more than 8-10
Participants assigned to this arm will be administered the sham device in clinic 5 days per week for 6 weeks
Device: Sham Device
Treatment with Neuro Rx Gamma
Device: Vielight Neuro Rx Gamma
Participants assigned to the intervention will be administered treatment with the Neuro Rx Gamma 5 days/week in clinic
Participant assigned to the sham device will be administered the sham device in clinic 5 days/week
Montgomery-Asberg Depression Rating Scale (MADRS)
Change in depression symptoms as measured by the Montgomery-Asberg Depression ( Rating Scale (MADRS). Scale is from 0-60, with higher score indicating high depression severity.
Time frame: Baseline to week 6
Clinical Global Impression Scale-Bipolar
Change in Clinical Global Impression Scale-Bipolar (CGI-BP). Scale from 1-7 with a higher means more severe illness.
Time frame: Change from baseline to week 6
Trails Making Test
Change in score of the Trails Making Test. Scored based on the total time in seconds it takes to complete each part, meaning a lower score is better and a higher score indicates greater cognitive impairment.
Time frame: Baseline to week 6
N-Back (2-Back)
Change in performance in N-Back (2-back)
Time frame: Baseline to week 6
World Health Disability Assessment Schedule 2.0 (WHODAS 2.0)
Change in quality of life as measured by the World Health Disability Assessment Schedule 2.0 (WHODAS 2.0). Scores range from 0 to 100, where higher scores indicate greater disability.
Time frame: Baseline to week 6
Pain Visual Analog Scale
Change in Pain Visual Analog Scale. The scale ranges from 0-100mm, with a higher number indicating more severe pain.
Time frame: Baseline to week 6
Rest electroencephalography (5min rest, eyes closed)
Change in characteristic features of rest electroencephalography. This is not a scale.
Time frame: Baseline to week 6
Stanford expectancy scale ratings
Stanford expectancy scale rating. The scale includes six items. Each of the six items is typically rated on an 11-point Likert scale (0-10), ranging from "not at all" to "extremely".
Time frame: Baseline
Young Mania Rating Scale (YMRS)
Change in Young Mania Rating Scale (YMRS). The Young Mania Rating Scale (YMRS) has a total score range of 0 to 60. A higher value on the YMRS does indicate greater severity of manic symptoms.
Time frame: Baseline to week 6
Columbia-Suicide Severity Rating Scale (C-SSRS)
Change in Columbia-Suicide Severity Rating Scale. The Columbia-Suicide Severity Rating Scale (C-SSRS) is a multi-part tool and does not have a fixed range, but it generally categorizes risk on a scale of 0-6 for the screener version (0=No Risk, 1-6=Increased Risk) or uses a 2-25 range for intensity of ideation. A higher values on the C-SSRS indicate more severe suicide risk/illness.
Time frame: Baseline to week 6
Device-related adverse events
Mean difference in device related adverse events between active and sham groups
Time frame: Baseline to week 6
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.
Of 363 interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vielight Inc.